ISRCTN ISRCTN84713819
DOI https://doi.org/10.1186/ISRCTN84713819
Protocol serial number NTR223
Sponsor The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)
Funder The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)
Submission date
20/12/2005
Registration date
20/12/2005
Last edited
15/05/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr A.G.S.C. Jansen
Scientific

University Medical Center Utrecht
Julius Center for Health Sciences and Primary Care
P.O. Box 85500
Utrecht
3508 GA
Netherlands

Phone +31 (0)30 253 8640
Email A.G.S.C.Jansen@umcutrecht.nl

Study information

Primary study designInterventional
Study designRandomised double blind placebo-controlled parallel group trial
Secondary study designRandomised controlled trial
Scientific titleEffectiveness and costs of combined influenza and pneumococcal vaccination in pre-school children with recurrent respiratory tract infections (RTI): a general practice-based randomised controlled trial
Study acronymPRIMAKid
Study objectivesCombined pneumococcal vaccination with influenza vaccination reduces the occurrence of respiratory tract infections (RTI) in children with recurrent RTI.
Ethics approval(s)Received from the local medical ethics committee
Health condition(s) or problem(s) studiedRespiratory tract infection (RTI)
Intervention1. Combined heptavalent pneumococcal conjugate vaccine twice and trivalent inactivated influenza vaccine (IV) twice with one repeated IV after 1 year (5 doses in total)
2. Combined IV twice and placebo vaccine (saline fluid) twice) with a repeated IV after 1 year
3. Control intervention: combined Hepatitis B vaccine twice and placebo vaccine (saline fluid) twice with one repeated Hepatitis B vaccination after 1 year
Intervention typeOther
Primary outcome measure(s)

Number of febrile RTI episodes

Key secondary outcome measure(s)

Severity and length of febrile RTI episodes as well as RTI-associated antibiotic prescriptions, medical visits, clinical laboratory diagnostic procedures, specialist referral and treatment with procedures like ventilatory tube placement or adeno-tonsillectomy, improvement of health-related quality of life, and reduced productivity loss of parents. Follow-up time varies from 7 to 22 months.

Completion date30/06/2005

Eligibility

Participant type(s)Patient
Age groupChild
Lower age limit18 Months
Upper age limit72 Months
SexAll
Target sample size at registration660
Key inclusion criteria1. Aged between 18 - 72 months
2. A history of two or more episodes of general practitioner attended RTIs
Key exclusion criteria1. No intention to move within 12 months to another region
2. Provision of informed consent
3. Good mastering of the Dutch language
4. Absence of chronic diseases such as asthma treated with corticosteroids or high-risk disease (such as palatoschisis, Down syndrome, cystic fibrosis, etc)
5. No previous influenza vaccination or pneumococcal vaccination or Hepatitis B vaccination
6. No hypersensitivity to eggs and/or antibiotics, and/or serious history of serious adverse events through vaccination
Date of first enrolment01/09/2003
Date of final enrolment30/06/2005

Locations

Countries of recruitment

  • Netherlands

Study participating centre

University Medical Center Utrecht
Utrecht
3508 GA
Netherlands

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan